-
1
-
-
2442563304
-
Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences
-
Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17.
-
(2004)
Gastroenterology
, vol.126
, pp. 1504-1517
-
-
Loftus, E.V.1
-
2
-
-
58149390157
-
An update on the epidemiology of inflammatory bowel disease in Asia
-
Thia KT, Loftus EV, Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167-82.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 3167-3182
-
-
Thia, K.T.1
Loftus, E.V.2
Sandborn, W.J.3
Yang, S.K.4
-
3
-
-
83755219473
-
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review
-
e42; quiz e30
-
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54 e42; quiz e30.
-
(2012)
Gastroenterology
, vol.142
, pp. 46-54
-
-
Molodecky, N.A.1
Soon, I.S.2
Rabi, D.M.3
Ghali, W.A.4
Ferris, M.5
Chernoff, G.6
Benchimol, E.I.7
Panaccione, R.8
Ghosh, S.9
Barkema, H.W.10
Kaplan, G.G.11
-
4
-
-
68149107759
-
Prevalence of ulcerative colitis and Crohn's disease in Japan
-
Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn's disease in Japan. J Gastroenterol 2009; 44: 659-65.
-
(2009)
J Gastroenterol
, vol.44
, pp. 659-665
-
-
Asakura, K.1
Nishiwaki, Y.2
Inoue, N.3
Hibi, T.4
Watanabe, M.5
Takebayashi, T.6
-
5
-
-
70949107842
-
Inflammatory bowel disease
-
Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-78.
-
(2009)
N Engl J Med
, vol.361
, pp. 2066-2078
-
-
Abraham, C.1
Cho, J.H.2
-
6
-
-
77952692062
-
Association between Helicobacter pylori infection and inflammatory bowel disease: A meta-analysis and systematic review of the literature
-
Luther J, Dave M, Higgins PD, Kao JY. Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm Bowel Dis 2010; 16: 1077-84.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 1077-1084
-
-
Luther, J.1
Dave, M.2
Higgins, P.D.3
Kao, J.Y.4
-
7
-
-
84866549438
-
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
-
Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, Leleiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13: R79.
-
(2012)
Genome Biol
, vol.13
, pp. R79
-
-
Morgan, X.C.1
Tickle, T.L.2
Sokol, H.3
Gevers, D.4
Devaney, K.L.5
Ward, D.V.6
Reyes, J.A.7
Shah, S.A.8
Leleiko, N.9
Snapper, S.B.10
Bousvaros, A.11
Korzenik, J.12
Sands, B.E.13
Xavier, R.J.14
Huttenhower, C.15
-
8
-
-
74049124863
-
World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010
-
Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, Gearry R, Goh KL, Hamid S, Khan AG, LeMair AW, Malfertheiner, Ouyang Q, Rey JF, Sood A, Steinwurz F, Thomsen OO, Thomson A, Watermeyer G. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010; 16: 112-24.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 112-124
-
-
Bernstein, C.N.1
Fried, M.2
Krabshuis, J.H.3
Cohen, H.4
Eliakim, R.5
Fedail, S.6
Gearry, R.7
Goh, K.L.8
Hamid, S.9
Khan, A.G.10
Le Mair, A.W.11
Malfertheiner Ouyang, Q.12
Rey, J.F.13
Sood, A.14
Steinwurz, F.15
Thomsen, O.O.16
Thomson, A.17
Watermeyer, G.18
-
9
-
-
0037018761
-
Maintenance infliximab for Crohn's disease: The ACCENT i randomised trial
-
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
-
(2002)
Lancet
, vol.359
, pp. 1541-1549
-
-
Hanauer, S.B.1
Feagan, B.G.2
Lichtenstein, G.R.3
Mayer, L.F.4
Schreiber, S.5
Colombel, J.F.6
Rachmilewitz, D.7
Wolf, D.C.8
Olson, A.9
Bao, W.10
Rutgeerts, P.11
-
10
-
-
28844473957
-
Infliximab for induction and maintenance therapy for ulcerative colitis
-
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
-
(2005)
N Engl J Med
, vol.353
, pp. 2462-2476
-
-
Rutgeerts, P.1
Sandborn, W.J.2
Feagan, B.G.3
Reinisch, W.4
Olson, A.5
Johanns, J.6
Travers, S.7
Rachmilewitz, D.8
Hanauer, S.B.9
Lichtenstein, G.R.10
De Villiers, W.J.11
Present, D.12
Sands, B.E.13
Colombel, J.F.14
-
11
-
-
0032849823
-
Review article: Efficacy of infliximab in Crohn's disease-induction and maintenance of remission
-
discussion 38
-
Rutgeerts PJ. Review article: efficacy of infliximab in Crohn's disease-induction and maintenance of remission. Aliment Pharmacol Ther 1999; 13 (Suppl. 4): 9-15; discussion 38.
-
(1999)
Aliment Pharmacol Ther
, vol.13
, pp. 9-15
-
-
Rutgeerts, P.J.1
-
12
-
-
33846242958
-
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
-
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
-
(2007)
Gastroenterology
, vol.132
, pp. 52-65
-
-
Colombel, J.F.1
Sandborn, W.J.2
Rutgeerts, P.3
Enns, R.4
Hanauer, S.B.5
Panaccione, R.6
Schreiber, S.7
Byczkowski, D.8
Li, J.9
Kent, J.D.10
Pollack, P.F.11
-
14
-
-
79955859430
-
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial
-
Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
-
(2011)
Gut
, vol.60
, pp. 780-787
-
-
Reinisch, W.1
Sandborn, W.J.2
Hommes, D.W.3
D'Haens, G.4
Hanauer, S.5
Schreiber, S.6
Panaccione, R.7
Fedorak, R.N.8
Tighe, M.B.9
Huang, B.10
Kampman, W.11
Lazar, A.12
Thakkar, R.13
-
15
-
-
34447523749
-
Certolizumab pegol for the treatment of Crohn's disease
-
Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
-
(2007)
N Engl J Med
, vol.357
, pp. 228-238
-
-
Sandborn, W.J.1
Feagan, B.G.2
Stoinov, S.3
Honiball, P.J.4
Rutgeerts, P.5
Mason, D.6
Bloomfield, R.7
Schreiber, S.8
-
16
-
-
34447515607
-
Maintenance therapy with certolizumab pegol for Crohn's disease
-
Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50.
-
(2007)
N Engl J Med
, vol.357
, pp. 239-250
-
-
Schreiber, S.1
Khaliq-Kareemi, M.2
Lawrance, I.C.3
Thomsen, O.O.4
Hanauer, S.B.5
Mc Colm, J.6
Bloomfield, R.7
Sandborn, W.J.8
-
17
-
-
84890620601
-
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis
-
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Jarnerot G, Hibi T, Rutgeerts P. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95.
-
(2014)
Gastroenterology
, vol.146
, pp. 85-95
-
-
Sandborn, W.J.1
Feagan, B.G.2
Marano, C.3
Zhang, H.4
Strauss, R.5
Johanns, J.6
Adedokun, O.J.7
Guzzo, C.8
Colombel, J.F.9
Reinisch, W.10
Gibson, P.R.11
Collins, J.12
Jarnerot, G.13
Hibi, T.14
Rutgeerts, P.15
-
18
-
-
79952788410
-
Review article: Remission rates achievable by current therapies for inflammatory bowel disease
-
Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 870-9.
-
(2011)
Aliment Pharmacol Ther
, vol.33
, pp. 870-879
-
-
Peyrin-Biroulet, L.1
Lemann, M.2
-
19
-
-
44649187924
-
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
-
Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53.
-
(2008)
Clin Gastroenterol Hepatol
, vol.6
, pp. 644-653
-
-
Peyrin-Biroulet, L.1
Deltenre, P.2
De Suray, N.3
Branche, J.4
Sandborn, W.J.5
Colombel, J.F.6
-
20
-
-
79957927386
-
Anti-TNF therapy: Safety aspects of taking the risk
-
Rosenblum H, Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011; 10: 563-8.
-
(2011)
Autoimmun Rev
, vol.10
, pp. 563-568
-
-
Rosenblum, H.1
Amital, H.2
-
21
-
-
0037145037
-
Integrins: Bidirectional, allosteric signaling machines
-
Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-87.
-
(2002)
Cell
, vol.110
, pp. 673-687
-
-
Hynes, R.O.1
-
22
-
-
84867576762
-
Exclusive antagonism of the alpha (4) beta(7) integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
-
Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, Kadambi VJ. Exclusive antagonism of the alpha(4) beta(7) integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012; 18: 2107-19.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. 2107-2119
-
-
Fedyk, E.R.1
Wyant, T.2
Yang, L.L.3
Csizmadia, V.4
Burke, K.5
Yang, H.6
Kadambi, V.J.7
-
23
-
-
0029826678
-
Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7
-
Hesterberg PE, Winsor-Hines D, Briskin MJ, Soler-Ferran D, Merrill C, Mackay CR, Newman W, Ringler DJ. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996; 111: 1373-80.
-
(1996)
Gastroenterology
, vol.111
, pp. 1373-1380
-
-
Hesterberg, P.E.1
Winsor-Hines, D.2
Briskin, M.J.3
Soler-Ferran, D.4
Merrill, C.5
Mackay, C.R.6
Newman, W.7
Ringler, D.J.8
-
24
-
-
84906921368
-
Pharmacokinetics and pharmacodynamics in cynomolgus monkeys of AMG 181, a fully human anti-?4?7 antibody for treating inflammatory bowel disease
-
Pan WJ, Lear SP, Patel SK, Prince PJ, Doherty DR, Tam CY, Sheckler CM, Hsu H, Rees WA, Anderson AA, Wisler JA, Reynhardt KO, Lynch JL, Brandvig JL, Wienkers LC, Borie DC. Pharmacokinetics and pharmacodynamics in cynomolgus monkeys of AMG 181, a fully human anti-?4?7 antibody for treating inflammatory bowel disease. J Crohns Colitis 2012; 6: pS14.
-
(2012)
J Crohns Colitis
, vol.6
, pp. pS14
-
-
Pan, W.J.1
Lear, S.P.2
Patel, S.K.3
Prince, P.J.4
Doherty, D.R.5
Tam, C.Y.6
Sheckler, C.M.7
Hsu, H.8
Rees, W.A.9
Anderson, A.A.10
Wisler, J.A.11
Reynhardt, K.O.12
Lynch, J.L.13
Brandvig, J.L.14
Wienkers, L.C.15
Borie, D.C.16
-
25
-
-
44849128021
-
Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease
-
Apostolaki M, Manoloukos M, Roulis M, Wurbel MA, Muller W, Papadakis KA, Kontoyiannis DL, Malissen B, Kollias G. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 2008; 134: 2025-35.
-
(2008)
Gastroenterology
, vol.134
, pp. 2025-2035
-
-
Apostolaki, M.1
Manoloukos, M.2
Roulis, M.3
Wurbel, M.A.4
Muller, W.5
Papadakis, K.A.6
Kontoyiannis, D.L.7
Malissen, B.8
Kollias, G.9
-
26
-
-
79953067215
-
A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes
-
Stefanich EG, Danilenko DM, Wang H, O'Byrne S, Erickson R, Gelzleichter T, Hiraragi H, Chiu H, Ivelja S, Jeet S, Gadkari S, Hwang O, Fuh F, Looney C, Howell K, Albert V, Balazs M, Refino C, Fong S, Iyer S, Williams M. A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 2011; 162: 1855-70.
-
(2011)
Br J Pharmacol
, vol.162
, pp. 1855-1870
-
-
Stefanich, E.G.1
Danilenko, D.M.2
Wang, H.3
O'Byrne, S.4
Erickson, R.5
Gelzleichter, T.6
Hiraragi, H.7
Chiu, H.8
Ivelja, S.9
Jeet, S.10
Gadkari, S.11
Hwang, O.12
Fuh, F.13
Looney, C.14
Howell, K.15
Albert, V.16
Balazs, M.17
Refino, C.18
Fong, S.19
Iyer, S.20
Williams, M.21
more..
-
27
-
-
0029665856
-
Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue
-
Wagner N, Lohler J, Kunkel EJ, Ley K, Leung E, Krissansen G, Rajewsky K, Muller W. Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature 1996; 382: 366-70.
-
(1996)
Nature
, vol.382
, pp. 366-370
-
-
Wagner, N.1
Lohler, J.2
Kunkel, E.J.3
Ley, K.4
Leung, E.5
Krissansen, G.6
Rajewsky, K.7
Muller, W.8
-
28
-
-
0031092633
-
Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells
-
Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997; 158: 2099-106.
-
(1997)
J Immunol
, vol.158
, pp. 2099-2106
-
-
Picarella, D.1
Hurlbut, P.2
Rottman, J.3
Shi, X.4
Butcher, E.5
Ringler, D.J.6
-
29
-
-
68549135114
-
Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody
-
Pullen N, Molloy E, Carter D, Syntin P, Clemo F, Finco-Kent D, Reagan W, Zhao S, Kawabata T, Sreckovic S. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol 2009; 157: 281-93.
-
(2009)
Br J Pharmacol
, vol.157
, pp. 281-293
-
-
Pullen, N.1
Molloy, E.2
Carter, D.3
Syntin, P.4
Clemo, F.5
Finco-Kent, D.6
Reagan, W.7
Zhao, S.8
Kawabata, T.9
Sreckovic, S.10
-
30
-
-
84861318436
-
Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis
-
Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012; 20: 1-18.
-
(2012)
Inflammopharmacology
, vol.20
, pp. 1-18
-
-
Thomas, S.1
Baumgart, D.C.2
-
31
-
-
27644441529
-
Natalizumab induction and maintenance therapy for Crohn's disease
-
Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25.
-
(2005)
N Engl J Med
, vol.353
, pp. 1912-1925
-
-
Sandborn, W.J.1
Colombel, J.F.2
Enns, R.3
Feagan, B.G.4
Hanauer, S.B.5
Lawrance, I.C.6
Panaccione, R.7
Sanders, M.8
Schreiber, S.9
Targan, S.10
Van Deventer, S.11
Goldblum, R.12
Despain, D.13
Hogge, G.S.14
Rutgeerts, P.15
-
32
-
-
34247884424
-
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial
-
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-83.
-
(2007)
Gastroenterology
, vol.132
, pp. 1672-1683
-
-
Targan, S.R.1
Feagan, B.G.2
Fedorak, R.N.3
Lashner, B.A.4
Panaccione, R.5
Present, D.H.6
Spehlmann, M.E.7
Rutgeerts, P.J.8
Tulassay, Z.9
Volfova, M.10
Wolf, D.C.11
Hernandez, C.12
Bornstein, J.13
Sandborn, W.J.14
-
33
-
-
33644584352
-
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
-
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
-
(2006)
N Engl J Med
, vol.354
, pp. 899-910
-
-
Polman, C.H.1
O'Connor, P.W.2
Havrdova, E.3
Hutchinson, M.4
Kappos, L.5
Miller, D.H.6
Phillips, J.T.7
Lublin, F.D.8
Giovannoni, G.9
Wajgt, A.10
Toal, M.11
Lynn, F.12
Panzara, M.A.13
Sandrock, A.W.14
-
34
-
-
22844438117
-
Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences
-
Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med 2005; 353: 414-6.
-
(2005)
N Engl J Med
, vol.353
, pp. 414-416
-
-
Berger, J.R.1
Koralnik, I.J.2
-
35
-
-
26844538111
-
Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis
-
author reply 44-6
-
Berger T, Deisenhammer F. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis. N Engl J Med 2005; 353: 1744-6; author reply 44-6.
-
(2005)
N Engl J Med
, vol.353
, pp. 1744-1746
-
-
Berger, T.1
Deisenhammer, F.2
-
36
-
-
37548998990
-
Treating multiple sclerosis in the natalizumab era: Risks benefits clinical decision making and a comparison between North American and European Union practices
-
Giovannoni G, Kinkel P, Vartanian T. Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices. Rev Neurol Dis 2007; 4: 184-93.
-
(2007)
Rev Neurol Dis
, vol.4
, pp. 184-193
-
-
Giovannoni, G.1
Kinkel, P.2
Vartanian, T.3
-
37
-
-
22844445587
-
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
-
Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-8.
-
(2005)
N Engl J Med
, vol.353
, pp. 362-368
-
-
Van Assche, G.1
Van Ranst, M.2
Sciot, R.3
Dubois, B.4
Vermeire, S.5
Noman, M.6
Verbeeck, J.7
Geboes, K.8
Robberecht, W.9
Rutgeerts, P.10
-
38
-
-
57249089077
-
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin
-
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Cohen A, Bitton A, Baker J, Dube R, Landau SB, Vandervoort MK, Parikh A. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-7.
-
(2008)
Clin Gastroenterol Hepatol
, vol.6
, pp. 1370-1377
-
-
Feagan, B.G.1
Greenberg, G.R.2
Wild, G.3
Fedorak, R.N.4
Pare, P.5
Mc Donald, J.W.6
Cohen, A.7
Bitton, A.8
Baker, J.9
Dube, R.10
Landau, S.B.11
Vandervoort, M.K.12
Parikh, A.13
-
39
-
-
20444469332
-
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin
-
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Dube R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352: 2499-507.
-
(2005)
N Engl J Med
, vol.352
, pp. 2499-2507
-
-
Feagan, B.G.1
Greenberg, G.R.2
Wild, G.3
Fedorak, R.N.4
Pare, P.5
Mc Donald, J.W.6
Dube, R.7
Cohen, A.8
Steinhart, A.H.9
Landau, S.10
Aguzzi, R.A.11
Fox, I.H.12
Vandervoort, M.K.13
-
40
-
-
84863984524
-
Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study
-
Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I, Feagan BG. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18: 1470-9.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. 1470-1479
-
-
Parikh, A.1
Leach, T.2
Wyant, T.3
Scholz, C.4
Sankoh, S.5
Mould, D.R.6
Ponich, T.7
Fox, I.8
Feagan, B.G.9
-
41
-
-
84876269569
-
Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells
-
Pan W, Hsu H, Rees W, Lear S, Lee F, Foltz I, Rathanaswami P, Manchulenko K, Chan B, Zhang M, Xia X, Patel S, Prince P, Doherty D, Sheckler C, Reynhardt K, Krill C, Harder B, Wisler J, Brandvig J, Lynch J, Anderson A, Wienkers L, Borie D. Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol 2013; 169: 51-68.
-
(2013)
Br J Pharmacol
, vol.169
, pp. 51-68
-
-
Pan, W.1
Hsu, H.2
Rees, W.3
Lear, S.4
Lee, F.5
Foltz, I.6
Rathanaswami, P.7
Manchulenko, K.8
Chan, B.9
Zhang, M.10
Xia, X.11
Patel, S.12
Prince, P.13
Doherty, D.14
Sheckler, C.15
Reynhardt, K.16
Krill, C.17
Harder, B.18
Wisler, J.19
Brandvig, J.20
Lynch, J.21
Anderson, A.22
Wienkers, L.23
Borie, D.24
more..
-
42
-
-
84919401099
-
-
NIH. Safety tolerability, pharmacokinetics and pharmacodynamics of AMG 181 in healthy subjects and subjects with mild to moderate ulcerative colitis (NCT01164904) In, 7/1/2010 Edition, US National Institute of Health Available at last accessed 04 January 2014
-
NIH. Safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 181 in healthy subjects and subjects with mild to moderate ulcerative colitis (NCT01164904). In, 7/1/2010 Edition, US National Institute of Health, 2010. Available at http://clinicaltrials.gov/ct2/results? term=01164904&Search=Search (last accessed 04 January 2014).
-
(2010)
-
-
-
43
-
-
84919401098
-
-
NIH, AMG 181 phase 2 study in subjects with moderate to severe ulcerative colitis (NCT01694485). In, 9/24/2012 Edition, US National Institute of Health last accessed 04 January 2014
-
NIH. AMG 181 phase 2 study in subjects with moderate to severe ulcerative colitis (NCT01694485). In, 9/24/2012 Edition, US National Institute of Health, 2012. http://clinicaltrials.gov/ct2/results?term=01694485&Search =Search (last accessed 04 January 2014).
-
(2012)
-
-
-
44
-
-
84919401097
-
-
NIH, AMG 181 in subjects with moderate to severe Crohn's disease (NCT01696396). In, 9/27/2012 Edition, US National Institute of Health last accessed 04 January 2014
-
NIH. AMG 181 in subjects with moderate to severe Crohn's disease (NCT01696396). In, 9/27/2012 Edition, US National Institute of Health, 2012. http://clinicaltrials.gov/ct2/results? term=01696396&Search=Search (last accessed 04 January 2014).
-
(2012)
-
-
-
45
-
-
0023521441
-
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
-
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
-
(1987)
N Engl J Med
, vol.317
, pp. 1625-1629
-
-
Schroeder, K.W.1
Tremaine, W.J.2
Ilstrup, D.M.3
-
46
-
-
84919401096
-
-
National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0, Bethesda, MD: NCI, NIH, DHHS
-
National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. Bethesda, MD: NCI, NIH, DHHS, 2009.
-
(2009)
-
-
-
47
-
-
84872832486
-
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: Subgroup analyses from ULTRA 2
-
Sandborn WJ, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD, Thakkar R. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
-
(2013)
Aliment Pharmacol Ther
, vol.37
, pp. 204-213
-
-
Sandborn, W.J.1
Colombel, J.F.2
D'Haens, G.3
Van Assche, G.4
Wolf, D.5
Kron, M.6
Lazar, A.7
Robinson, A.M.8
Yang, M.9
Chao, J.D.10
Thakkar, R.11
-
48
-
-
84919342463
-
Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial
-
Sandborn W, Sands B, Rutgeerts P, Sankoh S, Rosario M, Milch C, Fox I. Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial. Inflamm Bowel Dis 2012; 18: S1.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. S1
-
-
Sandborn, W.1
Sands, B.2
Rutgeerts, P.3
Sankoh, S.4
Rosario, M.5
Milch, C.6
Fox, I.7
-
49
-
-
0037413468
-
Natalizumab for active Crohn's disease
-
Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32.
-
(2003)
N Engl J Med
, vol.348
, pp. 24-32
-
-
Ghosh, S.1
Goldin, E.2
Gordon, F.H.3
Malchow, H.A.4
Rask-Madsen, J.5
Rutgeerts, P.6
Vyhnalek, P.7
Zadorova, Z.8
Palmer, T.9
Donoghue, S.10
-
50
-
-
77952778634
-
Serum albumin concentration: A predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
-
Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010; 48: 297-308.
-
(2010)
Int J Clin Pharmacol Ther
, vol.48
, pp. 297-308
-
-
Fasanmade, A.A.1
Adedokun, O.J.2
Olson, A.3
Strauss, R.4
Davis, H.M.5
-
51
-
-
84858793037
-
Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms
-
Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46.
-
(2012)
Clin Pharmacol Ther
, vol.91
, pp. 635-646
-
-
Ordas, I.1
Mould, D.R.2
Feagan, B.G.3
Sandborn, W.J.4
-
52
-
-
59849104111
-
Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis
-
Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 1660-6.
-
(2008)
Inflamm Bowel Dis
, vol.14
, pp. 1660-1666
-
-
Lewis, J.D.1
Chuai, S.2
Nessel, L.3
Lichtenstein, G.R.4
Aberra, F.N.5
Ellenberg, J.H.6
-
53
-
-
70349508834
-
A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis
-
Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1081-8.
-
(2009)
Clin Gastroenterol Hepatol
, vol.7
, pp. 1081-1088
-
-
Turner, D.1
Seow, C.H.2
Greenberg, G.R.3
Griffiths, A.M.4
Silverberg, M.S.5
Steinhart, A.H.6
-
54
-
-
33745262396
-
Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease
-
Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 524-34.
-
(2006)
Inflamm Bowel Dis
, vol.12
, pp. 524-534
-
-
Konikoff, M.R.1
Denson, L.A.2
-
55
-
-
11144358509
-
Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis
-
Parsi MA, Shen B, Achkar JP, Remzi FF, Goldblum JR, Boone J, Lin D, Connor JT, Fazio VW, Lashner BA. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004; 126: 1280-6.
-
(2004)
Gastroenterology
, vol.126
, pp. 1280-1286
-
-
Parsi, M.A.1
Shen, B.2
Achkar, J.P.3
Remzi, F.F.4
Goldblum, J.R.5
Boone, J.6
Lin, D.7
Connor, J.T.8
Fazio, V.W.9
Lashner, B.A.10
-
56
-
-
33144460914
-
Laboratory markers in IBD: Useful magic or unnecessary toys
-
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-31.
-
(2006)
Gut
, vol.55
, pp. 426-431
-
-
Vermeire, S.1
Van Assche, G.2
Rutgeerts, P.3
|